Quarterly report pursuant to Section 13 or 15(d)

Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details)

v3.8.0.1
Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details)
$ / shares in Units, € in Millions
 3 Months Ended 9 Months Ended
Aug. 24, 2017
USD ($)
$ / shares
shares
Aug. 24, 2017
EUR (€)
shares
Sep. 30, 2017
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
 [1]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred revenue – current     $ 6,287,000   $ 6,287,000 $ 899,000
Novartis Pharma AG [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Cash received from sale of shares $ 5,000,000          
Number of shares sold | shares 539,131 539,131        
Common stock aggregate fair value $ 4,800,000          
Common stock closing price | $ / shares $ 8.93          
Common stock premium $ 200,000          
Novartis Pharma AG [Member] | Common Stock [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Cash received from sale of shares $ 5,000,000          
Number of shares sold | shares 539,131 539,131        
Sale of stock price per share | $ / shares $ 9.2742          
Common stock closing price | $ / shares $ 8.93          
Novartis Pharma AG [Member] | Les Laboratories Servier [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Repayments of debt $ 14,300,000 € 12.0        
Collaborative Arrangement [Member] | Novartis [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront payment received       $ 37,000,000    
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones         480,000,000  
Milestone received under the collaboration agreement         10,000,000  
XOMA-052 License Agreement [Member] | Novartis Pharma AG [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront payment received 15,700,000          
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones 438,000,000          
License agreement consideration received 30,000,000          
Milestone received under license agreement         0  
IL-1 Beta Target Agreement [Member] | Novartis Pharma AG [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront payment received 10,000,000          
Revenue recognized under licensing agreement     31,900,000      
XOMA-052 License Agreement and IL-1 Beta Target Agreement [Member] | Novartis Pharma AG [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront payment received 25,700,000          
License agreement consideration received 40,200,000          
Common stock premium 200,000          
XOMA-052 License Agreement and IL-1 Beta Target Agreement [Member] | Novartis Pharma AG [Member] | Les Laboratories Servier [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Repayments of debt 14,300,000          
Gevokizumab License Agreement [Member] | Novartis Pharma AG [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred revenue – current     $ 4,800,000   $ 4,800,000  
Amortization of deferred revenue $ 3,500,000          
[1] The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.